SCHEMBL3369975

SCHEMBL3369975

CCCC(=O)N1CCCC1c1nnc(-c2ccc(Cl)cc2)o1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 2/20 0.47
ALOX15B O15296 1/20 0.47
HCRTR1 O43613 9/20 0.47
HCRTR2 O43614 8/20 0.47
RAB9A P51151 1/20 0.44
TNKS O95271 1/20 0.43
PARP1 P09874 1/20 0.43
PARP2 Q9UGN5 1/20 0.43
TSHR P16473 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CPT1A P50416 1/20 0.42
PRCP P42785 1/20 0.42
ENPP2 Q13822 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3365251 0.88 HCRTR1 (0.48) HSD11B1ALDH1A1HCRTR1HCRTR2TNKS
SCHEMBL3369944 0.87 HSD11B1 (0.50) HSD11B1SMN1; SMN2ALDH1A1ALOX15BHCRTR1
SCHEMBL3370351 0.86 HSD11B1 (0.54) HSD11B1SMN1; SMN2ALDH1A1ALOX15BHCRTR1
SCHEMBL3366654 0.86 HSD11B1 (0.51) HSD11B1SMN1; SMN2ALDH1A1ALOX15BHCRTR1
SCHEMBL3366749 0.85 HSD11B1 (0.52) HSD11B1SMN1; SMN2ALDH1A1ALOX15BHCRTR1
SCHEMBL3364372 0.82 HSD11B1 (0.48) HSD11B1SMN1; SMN2ALDH1A1ALOX15BHCRTR1
SCHEMBL3367060 0.82 HCRTR1 (0.59) SMN1; SMN2ALDH1A1HCRTR1HCRTR2TNKS
SCHEMBL3370658 0.82 HSD11B1 (0.49) HSD11B1SMN1; SMN2ALDH1A1ALOX15BHCRTR1
SCHEMBL3367532 0.81 HCRTR1 (0.47) HSD11B1ALDH1A1HCRTR1HCRTR2RAB9A
SCHEMBL3368901 0.81 HCRTR1 (0.51) HSD11B1SMN1; SMN2ALDH1A1ALOX15BHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1532141-B1 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS GRUENENTHAL GMBH (DE) 2010-10-13 EP disclosed
US-7105538-B2 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2006-09-12 US disclosed
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants OPRD1, OPRK1, GRIN2C HSD11B1 545/4885SMN1; SMN2 1832/4885ALDH1A1 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.